Related Experiment Video
Updated: Dec 20, 2025
05:42
Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies
Published on: August 11, 2023
1.5K
Molecular patterns in salivary duct carcinoma identify prognostic subgroups
Simon A Mueller1,2,3, Marie-Emilie A Gauthier4,5,6, James Blackburn7,8
1The Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia. simon.mueller@insel.ch.
Summary
Salivary duct carcinoma (SDCa) is a rare cancer. Genetic analysis reveals TP53, PIK3CA, and HRAS mutations, alongside CDK4/6, ERBB2, and MYC amplifications, impacting survival. Androgen receptor (AR) and ERBB2 status define subgroups for targeted therapy.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Salivary duct carcinoma (SDCa) is an aggressive malignancy characterized by frequent metastasis and poor prognosis.
- Despite aggressive treatment, understanding the underlying molecular drivers of SDCa remains critical for improving patient outcomes.
Purpose of the Study:
- To comprehensively analyze genetic alterations in SDCa.
- To investigate the impact of these alterations on cancer pathways and clinical outcomes.
- To identify molecular subgroups with distinct clinical characteristics and prognoses.
Main Methods:
- Retrospective analysis of clinicopathologic data and tumor samples from 66 SDCa patients.
- Immunohistochemistry for Androgen Receptor (AR) assessment.
- Next-generation sequencing using the Illumina TruSight 170 gene panel for DNA mutation and copy number variation analysis.
Main Results:
- TP53 mutations (51%), PIK3CA (32%), HRAS (22%), and amplifications in CDK4/6 (22%), ERBB2 (21%), MYC (16%) were frequent. TP53 mutation and MYC amplification correlated with reduced disease-free survival.
- The PI3K pathway was most frequently altered. Cell cycle pathway alterations were associated with impaired survival.
- Three subgroups based on AR and ERBB2 status showed distinct molecular profiles and outcomes. AR-negative SDCa exhibited poor survival.
Conclusions:
- Genetic profiling of SDCa reveals frequent alterations in TP53, PIK3CA, HRAS, and cell cycle-related genes.
- AR and ERBB2 status are key in classifying SDCa into distinct molecular subgroups with prognostic relevance.
- Molecular patterns, including AR/ERBB2 status and MYC amplification, offer potential biomarkers for targeted therapy and prognosis in SDCa.
